KPRX earnings: next report 2026-08-07, real EPS beat/miss history, analyst consensus Buy, P/E -0.95. Updated 2026-07-23.
Kiora Pharmaceuticals (KPRX) Research Hub
Kiora Pharmaceuticals (KPRX) trades on NASDAQ, US in the Healthcare (Biotechnology) sector. As of 2026-09-11, shares last closed at 2.65 USD (+6.43%), in a range — insufficient history for 200-DMA. Valuation: trailing P/E -0.95, market cap 0.01B. This hub links to the full technical, earnings and options research available for KPRX.
Last updated 2026-09-11 · Source: FMP end-of-day prices (adjusted); indicators computed by SniperIQ
| Sector | Healthcare (Biotechnology) |
|---|---|
| Exchange | NASDAQ, US |
| Last close | 2.65 USD (+6.43%) |
| 52-week range | 2.28 USD – 2.75 USD |
| Trend regime | Range |
| 14-day RSI | 50.8 (Neutral) |
| Trailing P/E | -0.95 |
| Market cap | 0.01B |
| Dividend yield | 0.00% |
| Next earnings | 2026-08-07 |
Available research for KPRX
Covered Call on KPRX: how it works, illustrative setup around the real 2.65 USD price, max profit/loss, breakeven and when to use it. Educational.
Iron Condor on KPRX: how it works, illustrative setup around the real 2.65 USD price, max profit/loss, breakeven and when to use it. Educational.
Protective Put on KPRX: how it works, illustrative setup around the real 2.65 USD price, max profit/loss, breakeven and when to use it. Educational.
KPRX technical analysis: range, last 2.65 USD, RSI 50.8, 52w range 2.28 USD–2.75 USD, real support/resistance. Updated 2026-09-11.
Frequently asked questions
What sector is KPRX in?
Kiora Pharmaceuticals (KPRX) is classified under Healthcare (Biotechnology), listed on NASDAQ, US.
Is KPRX in an uptrend or downtrend?
As of 2026-09-11, KPRX is in a range — insufficient history for 200-DMA. See the full technical research page for support and resistance levels.
What is KPRX's trailing P/E ratio?
KPRX's trailing P/E is -0.95, with a market cap of 0.01B. See the earnings research page for full valuation detail.
When does KPRX next report earnings?
KPRX is next scheduled to report earnings on 2026-08-07, with a consensus EPS estimate of -0.47 USD.